Probable association between mRNA COVID-19 vaccine and opsoclonus-myoclonus-ataxia syndrome

Adnan Deniz; Defne Alikılıç; Merve Öztürk; Ömer Karaca; Mesut Güngör; Bülent Kara

doi:10.1016/j.jaapos.2022.12.001

Probable association between mRNA COVID-19 vaccine and opsoclonus-myoclonus-ataxia syndrome

J AAPOS. 2023 Apr;27(2):110-112. doi: 10.1016/j.jaapos.2022.12.001. Epub 2023 Jan 31.

Authors

Adnan Deniz¹, Defne Alikılıç², Merve Öztürk², Ömer Karaca², Mesut Güngör², Bülent Kara²

Affiliations

¹ Kocaeli University Faculty of Medicine, Department of Pediatrics, Division of Child Neurology, Kocaeli, Turkey. Electronic address: adnandeniz85@hotmail.com.
² Kocaeli University Faculty of Medicine, Department of Pediatrics, Division of Child Neurology, Kocaeli, Turkey.

Abstract

Opsoclonus-myoclonus-ataxia syndrome (OMAS) in children is most often of paraneoplastic origin, but it can also result from infectious processes, toxic and metabolic disorders, and organic events that cause damage to the brainstem or cerebellum. Post-vaccination OMAS has also been reported. We report the case of a 15-year-old girl who developed OMAS 24 hours after her first dose of mRNA COVID-19 (BioNTech) vaccine.

Publication types

Case Reports

MeSH terms

Adolescent
Ataxia
COVID-19 Vaccines* / adverse effects
COVID-19* / complications
Cerebellum
Female
Humans
Opsoclonus-Myoclonus Syndrome* / etiology

Substances

COVID-19 Vaccines